氟达拉滨、阿糖胞苷、粒细胞集落刺激因子(FLAG)联合吉妥珠单抗奥唑米星(GO)或伊达比星(IDA)治疗初诊核心结合因子(CBF)急性髓系白血病的生存与缓解回顾性比较:MD安德森174例患者经验
该研究在174例初诊CBF-AML患者中前瞻性比较FLAG-GO(N=65)与FLAG-IDA(N=109)方案。FLAG-GO组5年无复发生存率显著优于FLAG-IDA组(78% vs 59%,P=0.02)。FLAG-GO在诱导结束、巩固中期及巩固结束时的融合转录本分子清除率均更优。
要点
- FLAG-GO组5年无复发生存率78%,显著优于FLAG-IDA组的59%(P=0.02)。
- 多因素分析中FLAG-GO方案与更优无复发生存显著相关(P=0.04)。
- FLAG-GO组在诱导结束、巩固中期及巩固结束时的融合转录本深度分子清除均优于FLAG-IDA组。
核心结论
- FLAG-GO方案较FLAG-IDA方案在初诊CBF-AML患者中取得更好的临床结局,并通过qPCR评估融合转录本实现更深的分子清除。
研究设计与样本
- 前瞻性临床试验中连续纳入174例初诊CBF-AML患者,分别接受FLAG-GO方案(N=65)或FLAG-IDA方案(N=109)的诱导/巩固治疗。
主要发现
- FLAG-GO组5年无复发生存率为78%,FLAG-IDA组为59%,差异显著(P=0.02)。
- 无复发生存的多因素分析中,年龄(P=0.0001)、FLAG-GO方案(P=0.04)、巩固治疗结束时骨髓qPCR检测CBF相关融合转录本下降4个对数级(P=0.03)及附加细胞遗传学异常(P=0.03)为显著变量。
- 总生存的多因素分析中,较低年龄(P=0.0001)和诱导结束时转录本下降≥3个对数级(P=0.04)为显著预测变量,FLAG-GO方案有改善总生存的强烈趋势(P=0.06)。
- FLAG-GO方案在诱导结束(P=0.002)、巩固中期(P<0.01)和巩固结束(P<0.001)时疾病特异性融合转录本最佳下降方面均优于FLAG-IDA方案。
关键数值与推荐
- 5年无复发生存率:FLAG-GO组78% vs FLAG-IDA组59%(P=0.02)。
- 无复发生存多因素分析显著变量:年龄P=0.0001,FLAG-GO方案P=0.04,巩固结束qPCR融合转录本下降4 log P=0.03,附加细胞遗传学异常P=0.03。
- 总生存多因素分析显著变量:较低年龄P=0.0001,诱导结束转录本下降≥3 log P=0.04;FLAG-GO方案P=0.06。
- 融合转录本最佳下降比较:诱导结束P=0.002,巩固中期P<0.01,巩固结束P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fludarabine, cytarabine, GCSF (FLAG)-based induction/consolidation results in high remission rates in core binding factor (CBF) acute myelogenous leukemia. We treated 174 consecutive patients with newly diagnosed CBF-AML in a prospective clinical trial of FLAG-based induction/consolidation in combination with gemtuzumab ozogamicin (FLAG-GO; N = 65) or in combination with idarubicin (FLAG-IDA; N = 109). The 5 year RFS in the FLAG-GO cohort was significantly better than the FLAG-IDA cohort, 78% versus 59%, respectively (p-value = .02). In multivariate analysis for RFS, age (p = .0001), FLAG-GO regimen (p = .04), 4 log reduction in CBF-related fusion transcript by quantitative polymerase chain reaction (qPCR) in bone marrow samples at end of consolidation therapy (p = .03), and additional cytogenetic abnormalities (p = .03) were significant variables. Lower age (p = .0001) and 3 log or more transcript reduction at end of induction (p = .04) were significant variables predicting for better overall survival (OS), while there was strong trend for better OS with FLAG-GO (p = .06) regimen. FLAG-GO regimen was superior in optimal disease specific fusion transcript reduction at end of induction (p = .002), mid-consolidation (p < .01), and end of consolidation (p < .001) therapy. Induction/consolidation with FLAG-GO regimen results in better clinical outcomes in newly diagnosed patients with CBF-AML compared to FLAG-IDA and achieves deeper molecular clearance by qPCR assessment of the fusion transcripts.
引用
- Borthakur G, Ravandi F, Patel K, et al. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022. PMID: 36053747. doi:10.1002/ajh.26700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。